Acadia Pharmaceuticals Inc (ACAD) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Acadia Pharmaceuticals reported revenue of $1.07B, up 11.9% from $957.8M the year before. Net income was $391.0M (a 36.5% net margin), or $2.30 per diluted share. Gross margin was 91.7% and operating margin was 9.8%. Operating activities generated $109.8M of cash, leaving $105.1M of free cash flow. At fiscal year end, Acadia Pharmaceuticals held $1.56B in total assets against $336.8M in total liabilities, including $177.7M of cash and equivalents.
Open the full interactive Acadia Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Acadia Pharmaceuticals Key Stats
| Share Price | $18.62 |
|---|---|
| Market Cap | $3.22B |
| P/E Ratio | 8.1 |
| Revenue YoY Growth | +11.9% |
| 52-Week Range | $18.62 – $30.57 |
| Shares Outstanding | 171.6 million (basic, 2026 Q2) |
Acadia Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $441.8M | $484.1M | $517.2M | $726.4M | $957.8M | $1.07B |
| Cost of Goods Sold | $10.2M | $10.8M | $10.2M | $41.6M | $81.8M | $89.0M |
| Gross Profit | $431.5M | $473.3M | $507.1M | $684.8M | $876.0M | $982.5M |
| Operating Income | -$286.6M | -$170.4M | -$223.6M | -$73.4M | $230.8M | $104.8M |
| Pre-Tax Income | -$281.0M | -$167.5M | -$213.4M | -$51.0M | $258.1M | $138.9M |
| Income Tax | $611,000 | $351,000 | $2.5M | $10.2M | $31.6M | -$252.1M |
| Net Income | -$281.6M | -$167.9M | -$216.0M | -$61.3M | $226.5M | $391.0M |
| Diluted EPS | -$1.79 | -$1.05 | -$1.34 | -$0.37 | $1.36 | $2.30 |
Acadia Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $278.6M | $284.0M | $268.1M | $308.0M |
| Net Income | $71.8M | $273.6M | $3.6M | $31.5M |
| Diluted EPS | $0.42 | $1.61 | $0.02 | $0.18 |
Acadia Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $326.0M | $147.4M | $114.8M | $188.7M | $319.6M | $177.7M |
| Current Assets | $717.6M | $617.8M | $507.9M | $616.1M | $938.3M | $1.06B |
| Total Assets | $782.6M | $700.1M | $587.8M | $749.0M | $1.19B | $1.56B |
| Current Liabilities | $106.0M | $96.1M | $125.6M | $254.3M | $394.9M | $277.1M |
| Total Liabilities | $155.6M | $159.2M | $187.4M | $317.2M | $455.0M | $336.8M |
| Shareholders' Equity | $627.0M | $540.9M | $400.4M | $431.8M | $732.8M | $1.23B |
Acadia Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$136.2M | -$125.7M | -$114.0M | $16.7M | $157.7M | $109.8M |
| Cash From Investing | $192.5M | -$71.1M | $73.2M | $32.0M | -$30.5M | -$302.6M |
| Cash From Financing | $81.0M | $18.2M | $8.2M | $25.1M | $6.8M | $49.9M |
| Free Cash Flow | -$143.8M | -$126.8M | -$114.0M | $16.7M | $157.2M | $105.1M |
Figures from Acadia Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Acadia Pharmaceuticals financials page for every line item.
Acadia Pharmaceuticals Company Profile
| Ticker | ACAD |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001070494 |
Frequently Asked Questions
What was Acadia Pharmaceuticals' revenue in fiscal 2025?
Acadia Pharmaceuticals (ACAD) reported revenue of $1.07B for fiscal 2025.
What is Acadia Pharmaceuticals' annual revenue history?
Acadia Pharmaceuticals' annual revenue by fiscal year: 2020: $441.8M; 2021: $484.1M; 2022: $517.2M; 2023: $726.4M; 2024: $957.8M; 2025: $1.07B.
What was Acadia Pharmaceuticals' net income in fiscal 2025?
Acadia Pharmaceuticals reported net income of $391.0M for fiscal 2025.
What was Acadia Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Acadia Pharmaceuticals' diluted EPS was $2.30 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Acadia Pharmaceuticals generate in fiscal 2025?
Acadia Pharmaceuticals generated $105.1M of free cash flow in fiscal 2025.
What was Acadia Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Acadia Pharmaceuticals reported revenue of $308.0M.
How many shares of Acadia Pharmaceuticals are outstanding?
Acadia Pharmaceuticals reported a weighted average of 171.6 million basic shares outstanding in 2026 Q2.
What is Acadia Pharmaceuticals' market cap?
Based on its latest closing price, Acadia Pharmaceuticals (ACAD) has a market capitalization of about $3.22B.
When does Acadia Pharmaceuticals' fiscal year end?
Acadia Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Acadia Pharmaceuticals headquartered?
Acadia Pharmaceuticals lists its business address in San Diego, California in its SEC filings.